| Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
LATE-NC | Â | Â | Â | Â |
  Age at death | 1.16 (1.05–1.27) | 0.0029** | 1.27 (1.03–1.56) | 0.0264* |
  Sex (female) | 3.15 (0.80–12.43) | 0.1013 | Excluded | – |
  Braak NFT stages IV | 4.50 (1.04–19.51) | 0.0445* | 0.44 (0.05–3.90) | 0.4616 |
  Presence of Aβ deposits | 2.33 (0.55–9.86) | 0.2492 | Excluded | – |
  Thal phases 3–4 | 1.34 (0.31–5.85) | 0.6947 | Excluded | – |
  Amygdala GFA stage 4 | 21.78 (4.43–107.13) |  < 0.001** | 40.7 (2.81–590.25) | 0.0066** |
  Presence of AGs | 9.78 (1.89–50.59) | 0.0066** | Excluded | – |
  Saito AG stages II–III | 13.74 (2.99–63.20) |  < 0.001** | 2.02 (0.27–14.88) | 0.4915 |
  Infarctions in the neocortex | 0.58 (0.07–5.16) | 0.6255 | Excluded | - |
  Infarctions in the subcortical nuclei | 0.90 (0.21–3.91) | 0.8934 | Excluded | – |
Argyrophilic grains | Â | Â | Â | Â |
  Age at death | 1.07 (1.02–1.13) | 0.0058** | 1.07 (1.00–1.14) | 0.0428* |
  Sex (female) | 2.03 (0.64–6.44) | 0.2283 | Excluded | – |
  Braak NFT stage IV | 2.00 (0.57–7.00) | 0.2780 | 0.39 (0.07–2.24) | 0.2905 |
  Presence of Aβ deposits | 0.84 (0.32–2.20) | 0.7227 | Excluded | – |
  Thal phase 4 | 1.19 (0.18–7.65) | 0.8513 | Excluded | – |
  Amygdala GFA stage 4 | 16.13 (3.20–81.25) |  < 0.001** | 12.43 (1.97–78.37) | 0.0073** |
  Presence of LATE-NC | 9.78 (1.89–50.59) | 0.0066** | 1.70 (0.22–13.26) | 0.6111 |
  Infarctions in the neocortex | 2.11 (0.54–8.23) | 0.2817 | Excluded | – |
  Infarctions in the subcortical nuclei | 0.91 (0.30–2.70) | 0.8599 | Excluded | – |
Severe neuronal loss in the amygdala | Â | Â | Â | Â |
  Age at death | 1.05 (0.96–1.15) | 0.2858 | 0.98 (0.88–1.10) | 0.7429 |
  Sex (female) | 0.42 (0.04–3.97) | 0.4491 | Excluded | – |
  Braak NFT stage IV | 1.27 (0.13–12.50) | 0.8361 | Excluded | – |
  Presence of Aβ deposits | 0.20 (0.02–1.91) | 0.1632 | Excluded | – |
  Amygdala GFA stage 4 | 3.39 (0.51–22.75) | 0.2080 | 0.73 (0.06–8.24) | 0.7978 |
  Saito AG stage I | 1.61 (0.16–16.09) | 0.6846 | Excluded | – |
  Saito AG stages II–III | 18.33 (1.88–178.98) | 0.0123* | 21.00 (1.34–328.20) | 0.0300* |
  Saito AG stage III | 130.00 (9.62–1757.58) |  < 0.001** | Excluded | – |
  Presence of LATE-NC | 4.92 (0.71–34.06) | 0.1068 | 1.67 (0.12–23.23) | 0.7026 |
  Infarctions in the neocortex | 1.96 (0.18–21.02) | 0.5772 | Excluded | – |
  Infarctions in the subcortical nuclei | 0.70 (0.07–7.16) | 0.7637 | Excluded | – |